DeVry Receives “Neutral” Rating from Zacks (DV)
DeVry (NYSE:DV)‘s stock had its “neutral” rating reiterated by Zacks in a research report issued on Monday, Stock Ratings Network.com reports. They currently have a $32.00 price objective on the stock. Zacks‘ price objective indicates a potential upside of 3.59% from the stock’s previous close.
Zacks‘ analyst wrote, “DeVry reported mixed fourth-quarter fiscal 2013 results wherein the company beat earnings but delivered in-line revenues as the flagship DeVry University continues to struggle. Moreover, management expects the weak enrollment trends and revenue decline at DeVry University to outweigh further cost savings and growth in other institutions in fiscal 2014. Despite the near-term sluggishness, we believe the company has long-term value. Its diversified portfolio of programs, regular strategic acquisitions and a debt-free balance sheet give it a competitive advantage. The company is also seeing continued strength in its health care and international businesses. The performance improvement plan to align costs, regain enrollment growth and make growth investments look impressive. We, however, prefer to remain Neutral on the stock until we see improving enrollment trends at DeVry University. The continued challenged regulatory environment remains a persistent overhang.”
Shares of DeVry (NYSE:DV) traded down 0.97% during mid-day trading on Monday, hitting $30.59. 86,592 shares of the company’s stock traded hands. DeVry has a 52 week low of $20.37 and a 52 week high of $34.51. The stock’s 50-day moving average is $30.4 and its 200-day moving average is $30.55. The company has a market cap of $1.926 billion and a P/E ratio of 18.74.
DeVry (NYSE:DV) last released its earnings data on Thursday, August 8th. The company reported $0.51 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.41 by $0.10. The company had revenue of $480.00 million for the quarter, compared to the consensus estimate of $481.42 million. During the same quarter in the previous year, the company posted $0.47 earnings per share. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. Analysts expect that DeVry will post $2.30 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Thomson Reuters/Verus downgraded shares of DeVry from a “buy” rating to a “hold” rating in a research note to investors on Monday, August 19th. Separately, analysts at Ned Davis Research upgraded shares of DeVry from a “neutral” rating to a “buy” rating in a research note to investors on Monday, August 19th. Finally, analysts at BMO Capital Markets cut their price target on shares of DeVry from $34.00 to $28.00 in a research note to investors on Friday, August 9th. They now have a “market perform” rating on the stock. Twelve research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $29.80.
DeVry Inc (NYSE:DV) is a provider of educational services and the parent organization of Advanced Academics, American University of the Caribbean School of Medicine, Becker Professional Education, Carrington College and Carrington College California, Chamberlain College of Nursing, DeVry Brasil, DeVry University, Ross University School of Medicine and Ross University School of Veterinary Medicine.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.